Stockreport

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance [Seeking Alpha]

Protalix BioTherapeutics, Inc. (DE)  (PLX) 
PDF PLX's growth thesis centers on Elfabrio's EU approval and once-every-4-weeks dosing, offering a clear competitive and patient adherence advantage. Chiesi's contributi [Read more]